Effects of low-dose hydrocortisone and hydrocortisone plus fludrocortisone in adults with septic shock: a protocol for a systematic review and meta-analysis of individual participant data. Issue 12 (2nd December 2020)

• Record Type: Journal Article
• Authors: Annane, Djillali; Pirracchio, Romain; Billot, Laurent; Waschka, Andre; Chevret, Sylvie; Cohen, Jeremy; Finfer, Simon; Gordon, Anthony; Hammond, Naomi; Myburgh, John; Venkatesh, Balasubramanian; Delaney, Anthony
• Other Names: author non-byline.; Arabi Yaseen author non-byline.; Bollaert Pierre Edouard author non-byline.; Briegel Josef author non-byline.; Keh Didier author non-byline.; Liu Ling author non-byline.; Umberto G author non-byline.; Mirea Liliana author non-byline.; Charles L author non-byline.; Tilouche Nejla author non-byline.; Tongyoo Surat author non-byline.; Zheng Ruiqiang author non-byline.
• Is Part Of: BMJ open. Volume 10:Issue 12(2020)
• Publication Date: 2020-12-02
• Subjects: adult intensive & critical care -- clinical trials -- clinical pharmacology; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2020-040931
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Introduction: The benefits and risks of low-dose hydrocortisone in patients with septic shock have been investigated in numerous randomised controlled trials and trial-level meta-analyses. Yet, the routine use of this treatment remains controversial. To overcome the limitations of previous meta-analyses inherent to the use of aggregate data, we will perform an individual patient data meta-analysis (IPDMA) on the effect of hydrocortisone with or without fludrocortisone compared with placebo or usual care on 90-day mortality and other outcomes in patients with septic shock. Methods and analysis: To assess the benefits and risks of hydrocortisone, with or without fludrocortisone for adults with septic shock, we will search major electronic databases from inception to September 2020 (Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE and Latin American Caribbean Health Sciences Literature), complimented by a search for unpublished trials. The primary analysis will compare hydrocortisone with or without fludrocortisone to placebo or no treatment in adult patients with septic shock. Secondary analyses will compare hydrocortisone to placebo (or usual care), hydrocortisone plus fludrocortisone to placebo (or usual care), and hydrocortisone versus hydrocortisone plus fludrocortisone. The primary outcome will be all cause mortality at 90 days. We will conduct both one-stage IPDMA using mixed-effect models and machine learning with targeted maximum likelihood analyses. We will assess the risk of bias related to unshared data and related to the quality of individual trial. Ethics and dissemination: This IPDMA will use existing data from completed randomised clinical trials and will comply with the ethical and regulatory requirements regarding data sharing for each of the component trials. The findings of this study will be submitted for publication in a peer-review journal with straightforward policy for open access. PROSPERO registration number: CRD42017062198.